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1.1 Primary Immunodeficiency Disorders 
 
Primary immunodeficiency disorders (PID) include a large heterogeneous group of 
inherited diseases sharing either a poor or absent function in one or more components 
of the immune system. More than 350 different monogenic immune disorders and 
corresponding genes have been identified to date and many new others are 
continuously being recognized. Though rare, these disorders are chronic and severe 
and timely diagnosis can be lifesaving, at least for identifying the most suitable drug 
treatment(s) until bone marrow transplantation can take place. Moreover, even in 
single PID gene mutation, a genotype-phenotype correlation is often lacking, due to 
frequent cases of reduced penetrance and variable expressivity, as well as to a wide 
phenotypic heterogeneity due to allelic series.1 Despite the variability of clinical 
presentations, most disorders involve autoimmunity and immune dysregulation, 
strongly associated with frequent infections.  
With the exception of IgA deficiency (1/300-500), PIDs are more frequent than 
previously believed, with an estimated prevalence of 1 in 1200 live births. PIDs are 
essentially classified based on the component of the immune system that is involved, 
either the adaptive or the innate immunity (Figure 1). They are also distinct from 
secondary immune-deficiencies, resulting from other causes, such as viral or bacterial 
infections, malnutrition, treatments that induce immunosuppression or 
immunoglobulin loss.2,3 In February 2017, the International Union of Immunological 
Societies (IUIS) established the classification of the inborn errors of immunity:4 
 immune-deficiencies affecting cellular and humoral immunity;  
 combined immune-deficiencies with associated or syndromic features;  
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 predominantly antibody deficiencies;  
 diseases of immune dysregulation;  
 congenital defects of phagocyte number or function;  
 defects in intrinsic and innate immunity;  
 autoinflammatory disorders;  
 complement deficiencies;  
 phenocopies of inborn errors of immunity.  
Figure 1: Archetypal primary immunodeficiencies in the context of the classical immune response (from 






















1.2 Pathogenic mechanisms of PID 
 
1.2.1 Disorders of innate immunity 
The first line of defense against potential pathogens is represented by the innate 
immune system. Responses and reactions are not specific to each particular pathogen, 
reflecting a simple and unrefined mechanism that is, however, highly conserved in 
vertebrates, invertebrates and plants. The innate immune system recognizes microbes 
through a class of proteins found either inside or on the surface of the immune cells, 
termed pattern recognition receptors (PRRs), binding unique proteins of various 
microorganisms. A major class of PRRs are called toll-like receptors (TLRs), and they are 
responsible for triggering host cell expression in response to pathogens. Upon contact 
with these microbes, TLRs send internal messages to the nucleus of the cell to secrete 
cytokines, which stimulate the immune system to fight against the invading 
microorganisms. The innate immune system relies on the recognition of particular 
types of molecules that are common to many pathogens but are absent in the host.  
These pathogen-associated molecules (called pathogen-associated immune-
stimulants) may induce two different innate immune responses: the inflammatory 
responses and the phagocytosis. Both these responses can occur quickly, even if the 
host has not previously been exposed to a particular pathogen. Numerous cells and 
proteins are involved in this response, including phagocytes, dendritic cells and 
complement proteins. Phagocytes are primarily responsible for phagocytosis, the 
process by which pathogen material is engulfed and eliminate by a cell.5 
Complement system consists of about 20 interacting soluble proteins that are 
synthetized mainly by the liver and circulate in the blood and extracellular fluid. Most 
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of them are inactive until they are triggered by an infection. Their function is to 
identify and opsonize foreign antigens, so that they can be eliminated. The early 
complement components are activated first. There are three sets of these, belonging 
to three distinct pathways of complement activation: the classical pathway, the lectin 
pathway, and the alternative pathway. The early components of all three pathways act 
locally to activate C3, which is the pivotal component of complement. The early 
components and C3 are all pro-enzymes, that are activated sequentially by proteolytic 
cleavage. The classical pathway is activated by IgG or IgM antibody molecules bound to 
the surface of a microbe. The lectine pathway is mediated by mannan-binding lectin, a 
serum protein that forms clusters of six carbohydrate-binding heads around a central 
collagen-like stalk, and binds specifically mannose and fucose residues in bacterial cell 
walls. In the alternative pathway, C3 is spontaneously activated at low levels and can 
attach to both host cells and pathogens. Host cells produce a series of proteins that 
prevent the complement reaction from proceeding on their cell surfaces. Because 
pathogens lack these proteins, they are singled out for destruction. Activation of the 
classical or lectin pathways also activates the alternative pathway through a positive 
feedback loop, amplifying their effects.  
Another key-component of the innate immunity system is represented by the Natural 
Killer (NK) cells. Their function is to destroy virus-infected cells by inducing their 
apoptosis. NK cells do not express antigen-specific receptors, so they can monitor the 
level of class I Major Histocompatibility Complex (MHC) proteins, a sophisticated and 
highly polymorphic group of genes in vertebrates that code for a large family of cell-
surface glycoproteins. The presence of high levels of these proteins inhibits the killing 
9 
 
activity of NK cells that, therefore, selectively kill cells expressing low levels class I MHC 
proteins, including both virally-infected cells and some cancer cells.  
Defects in the development and function of anyone of these elements may lead to 
PIDs. Defects of phagocyte number or function involve chronic granulomatous disease 
(CGD), severe pyogenic bacterial infection of skin and mucosal, and leukocyte adhesion 
deficiency (e.g. some of the genes found with mutations in these disorders are ELANE, 
WAS, VPS13B, GATA2). Defects in complement system entail deficiency in early 
complement pathway (C1q, C1r, C2, C4), in late complement pathway (C5, C6, C7, C8, 
C9) and in C3 and regulatory components. Also the family of cytokines may be subject 
to defects, in particular the group of interleukins (ILs) and interferon (IFN-α, IFN-β and 
IFN-γ).2,6 
 
1.2.2 Disorders of adaptive immunity 
The adaptive immunity is a sophisticated defensive response, unique prerogative of 
vertebrates. Adaptive responses are highly specific to each particular pathogen and 
can also provide long-lasting protection. Being this type of defensive answer more 
precise but also more powerful, it is important that the system can clearly distinguish 
foreign antigens from the self. Any substance capable of eliciting an adaptive immune 
response is referred to as an antigen (antibody generator). The activity of the adaptive 
immune system is carried out by blood cells called lymphocytes, which include B cells 
producing antibody (humoral) responses and T cells involved in cell-mediated immune 
responses. In antibody responses, B cells are activated to secrete antibodies, which are 
proteins called immunoglobulins. The antibodies circulate in the bloodstream and 
pervade any other body fluid and district. They bind specifically the foreign antigen 
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thus stimulating their further production and inactivating viruses and microbial toxins. 
In the cell-mediated immune responses, activated T cells react directly against a 
foreign antigen that is presented on the surface of a host cell. The two different 
response systems are so intertwined in their activities so that the defect of one is often 
enough to entail a combined disorder: since B-cell-mediated antibody production 
requires intact T-cell function, most T-cell defects lead to combined (B- and T-cell) 
immunodeficiency disorders (CIDs).2,6 
 
1.2.3 Autoimmunity 
The balance between host defense and protection against self-directed immune attack 
is essential and depends on lymphocyte proliferation and immune tolerance. The 
immune system becomes tolerant to self-antigens through the process of central and 
peripheral tolerance. The main mechanism for the induction of central tolerance in 
bone marrow and thymus (for B- and T-cells, respectively) consists in the deletion of 
high-affinity auto-reactive lymphocytes. The main mechanisms for peripheral tolerance 
are anergy, antigene ignorance, deletion by apoptosis, effect of inhibitory receptors 
and inhibition of auto-reactive lymphocytes by T regulatory (Tregs) cells.7 In PID 
patients, inflammation and persistent antigen presentation due to recurrent infections 
are essential mechanisms for autoimmunity.7  
There are PIDs associated with autoimmune disease due to dysregulation of the whole 
immune system. Generally, lymphocytes may be present though dysfunctional, 
allowing for the development of excessive auto-reactivity and resulting in autoimmune 
disease and/or other symptoms of immune dysregulation. Autoimmune 
lymphoproliferative syndrome (ALPS), hemophagocytic lymphohistiocytosis (HLH) and 
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many other disorders belong to this category. In particular, ALPS is one of the first 
well-characterized human genetic disorders of the apoptosis and represents a very 
good example of how the improvement in genomic technologies in the latest years has 






1.3 Classical diagnostics of PID 
The current diagnostic approach to PIDs is dominated by time-consuming phenotypic 
and functional characterization. The diagnostic procedure for PIDs is a multistep 
process involving collection of a detailed personal and family history and data from 
several complex laboratory assays, thus allowing to define the immunologic defect.9 
In the latest few years, molecular genetic testing has become an essential diagnostic 
tool for PIDs as it often provides a conclusive diagnosis, assists in genetic counseling, 
permits early prenatal diagnosis and carrier identification, determines the diagnosis in 
atypical cases, affords genotype-phenotype correlation, and allows pre-symptomatic 
identification of patients with PIDs.10 
Sanger sequencing has played the crucial final step common to every genetic approach 
for many years and still represents the gold standard for DNA sequencing, the “first 
generation” process of reading the sequence of nucleotides present in a DNA 
molecule, thus confirming the presence of nucleotide variants in genes of interest.11 
Unfortunately, Sanger sequencing is not only laborious, expensive and time-
consuming, but it is also not available in a diagnostic setting for many genes in 





1.4 Next Generation Sequencing  
The advent of the Next Generation Sequencing (NGS) has solved and overcome most 
problems in both diagnostic and genetic research.  
In particular, in PIDs, NGS has driven the rapid increase in the number of recognizable 
disorders, often hampered by the wide heterogeneity of the many genetically diverse 
but phenotypically overlapping diseases, and has led to the discovery of new genes 
implicated in well-defined biological pathways, revisiting frequencies and broadening 
the phenotypic spectra.4,12,13 
NGS is a revolutionary diagnostic tool for genetic investigations, allowing the 
simultaneous analysis of multiple genes and the effective detection of gene mosaicism. 
There are a variety of different NGS technological platforms making use of different 
sequencing chemistries.14,15 Nevertheless, most of these share a common set of 
features concerning sequencing reactions such as: i) taking place in parallel, at the 
same time, ii) micro scaled so that a very high number of genes can be accommodated 
on the same chip, iii) requiring a very tiny amount of DNA per test, iv) cheaper than 
Sanger sequencing, v) producing shorter reads (typically 50-700 nt in length). 
Till now, most clinical applications have been in diagnostic testing for hereditary 
disorders and, more recently, for risk screening for hereditary cancers and therapeutic 
decision-making for somatic cancers. The testing target has evolved from hotspot 
panels, actionable gene panels, and disease-focused panels to more comprehensive 
panels such as the targeted whole exome and the unbiased whole genome, 
sequencing approaches these latter that are beginning to emerge in specific cases also 
on a diagnostic setting. Panel-based testing is more practical at the present time, 
especially in small labs, and is still widely applied in clinical applications. The hotspot 
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panel is a collection of frequently mutated hotspots that are either clinically actionable 
or with diagnostic/prognostic significance. The actionable gene panels evolved from 
hotspot panels by including all exons of targeted genes (or all clinical relevant regions) 
so that other pathogenic mutations outside frequently mutated sites can be 
interrogated.  
The disease-focused panels are comprised of the genes for a particular disease and are 
largely used to screen for the risk of inherited diseases, or to diagnose suspected 
genetic diseases. The common feature of these panels is to focus on genes known in 
the literature to be associated or related to the disease. Although disease-focused 
panels have gained popularity, clinical laboratories are facing serious financial and 
practical challenges associated with 1) the development and validation of different 
disease-focused panels according to the international guidelines; 2) the limited 
number of samples in need of molecular testing for any given disease at any given 
time; 3) the requirement to constantly update the content of existing panels. The 
challenges that clinicians are beginning to face today involve the choice between 
starting their analysis with a disease-targeted test versus jumping immediately to 
exome (WES) or genome (WGS) approaches. Besides cost issues, laboratories hesitate 
to switch to large unbiased approaches to avoid facing with the hundreds of variants 
with unknown clinical significance detected when WES and WGS are applied and that 
is why targeted testing will remain a cornerstone of the diagnostic evaluation for at 
least a few more years.16,17  
Regardless of the target size, the NGS technology is based on the parallel sequencing 
of multiple small fragments of a given DNA target, which are ligated to proper 
adaptors and pooled in so-called “libraries” for the successive sequencing, rather than 
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on the sequencing of single fragments like in the Sanger sequencing technology. Next 
generation methods of DNA sequencing have therefore three main steps: (1) creation 
of DNA libraries including the whole target DNA, first captured in the form of DNA 
segments that are then ligated to custom linkers, (2) amplification of the libraries using 
clonal methods to separate each fragment, and (3) sequencing of each fragment of the 
library using one of several different chemistries.11 
The library preparation can take place through different technologies generally based 
on probe hybridization to enrich sequencing libraries or based on highly multiplexed 
PCR reactions (Figure 2). Amplicon assays offer a slight advantage in being able to work 
with smaller quantities of input DNA, often down to 10ng. Hybridization assays 
generally require more input DNA, typically ~500 ng. Hybridization protocols start with 
random shearing of the DNA, followed by “capture” of the randomly sheared 
overlapping fragments with long oligonucleotide (oligo) baits. This allows independent 
sequencing of a large number of unique fragments. Any duplicates (assay artifacts) can 
be easily identified and removed, leaving high-quality data for analysis. Because the 
fragments are randomly sheared they should not align perfectly with one another and 
if they do, they are most certainly duplicates. Hybridization capture approach generally 
demonstrates better uniformity but can undergo off-target capture of sequences with 
high levels of repetition or low complexity (i.e., the Human Histocompatibility Locus 
region). Hybridization assay protocols are more time consuming and require large 
numbers of manual steps. 
The PCR-based method is more efficient with lower amounts of DNA and has usually 
higher on-target rates. Tricky quality parameters of each runs, such as limited 
coverage, low variant frequency, and vicinity to read starts/ends, lead to a significant 
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number of potential false positive and false negative results. Primer competition and 
non-uniform amplification of target regions caused by varied GC content or amplicon 
length for example in the presence of an insertion (under-represented) or deletion 
(over-represented), contribute to variation in amplification efficiency. PCR-based 
approaches are usually faster with fewer steps. It is important to note, however, that 
PCR itself is the most common source of bias and error in any enrichment assay, so the 
faster protocol is ultimately balanced by the requirement for high-quality data, and the 
additional time required to validate potential false positive results.  
Performance, namely the likelihood that the assay can detect all variants present in 
any region of interest, avoiding false negatives and false positives, should be a key 
requirement for all applications. The most common reason for false negatives in a 
targeted sequencing assay is poor coverage at the locus. The most common cause of 
false positives are artifacts introduced by PCR polymerases, even when using 
proofreading enzymes. Hybridization assays use very few PCR cycles, in comparison to 
amplicon assays, and therefore the data is less “noisy”. 
Price is also a factor to be taken into consideration: for larger regions, hybrid-based 
panels are very convenient; for smaller regions, amplicon tests may be cheaper 
because the lower cost of a small number of the primers.  
In any case, a limitation of targeted re-sequencing, whatever target capture procedure, 
is that probes and oligos are based on a reference sequence, and variations that 
significantly deviate from the reference, as well as large insertion/deletion mutations, 
are not always going to be determined.18  
17 
 
The following sequencing step can mainly take place through two technological 
platforms supplied by two distinct companies: the Ion Torrent Personal Genome 
Machine by ThermoFisher and the HiSeq 2000 by Illumina. 
The Ion Torrent PGM “harnesses the power of semiconductor technology” detecting 
the protons released as nucleotides are incorporated during synthesis. DNA fragments 
with specific adapter sequences are linked to and then clonally amplified by emulsion 
PCR on the surface of 3-micron diameter beads, known as Ion Sphere Particles. The 
templated beads are loaded into proton-sensing wells that are fabricated on a silicon 
wafer and sequencing is primed from a specific location in the adapter sequence. As 
sequencing proceeds, each of the four bases is introduced sequentially. If bases of that 
type are incorporated, protons are released and a signal is detected proportional to 
the number of bases incorporated. Conversely, Illumina has adopted a sequencing-by-
synthesis approach, utilizing fluorescently labeled reversible-terminator nucleotides, 
on clonally amplified DNA templates immobilized to an acrylamide coating on the 
















Figure 2: AmpliSeq and HaloPlex are the protocols used in this study. Noteworthy, though reported as 








































Since its development, Next-Generation Sequencing (NGS) has had outstanding 
implications on both clinical diagnosis and research applications to study simple 
Mendelian disorders, such as PIDs. In the last few years, our knowledge about PIDs 
etiology has largely increased resulting in the discovery of novel genes and the 
recognition of new diseases, a step forward the establishment of robust phenotype-
genotype correlations.  
The present project has focused on: 
1) the identification of the underlying genetic causes of already known and unknown 
PIDs, particularly of bone marrow failure and autoimmune and idiopathic cytopenias 
and lymphoproliferations, 
2) the improvement of our knowledge about clinically overlapping phenotypes through 
the genetic characterization of the corresponding patients, and 
3) the optimization of the diagnostic work-up in order to administer disease specific 
treatments to patients.  
Indeed, the correct identification of the pathogenic mechanisms underlying these 
disorders represents a challenge with many implications for effective diagnostic work-































3.1 Patient recruitment and DNA extraction 
 
Patients were selected by the Hematology Unit of Istituto Giannina Gaslini based on a 
clinical history highly evocative of primary immunological defects, without distinction 
of ethnicity, age and sex. The inclusion criteria were: 
 peripheral and/or central cytopenia and/or 
 lymphoprolipheration and/or 
 autoimmunity 
All adult subjects provided written informed consent to participate to this study, while 
parental consent was obtained for children. A total of 149 patients (one of these 
analyzed for both panel 1 and panel 2 to increase chances for genetic definition) were 
involved in three different sets of analysis: 
1. The first cohort included 51 patients that were analyzed for 146 genes associated 
with haemato-immuno diseases.  
2. The second cohort included 69 patients that were analyzed for 315 genes 
associated with haemato-immuno-reumato diseases.  
3. The third cohort included 30 patients that were analyzed for 58 genes associated 
with Bone Marrow failure and immune-dysregulations. 
Forty-six of these patients had had previous genetic studies based on a candidate gene 
approach with no identified genetic defects.  
DNA was isolated from peripheral blood samples from patients, and parents when 
available, and extracted by using QIAamp DNA Blood Midi kit. Quality and quantity of 




3.2 Enrichment/amplification design and sequencing 
 
DNA capture probes and primers were designed based on the GRCh37/hg19 build of 
the human references genome. The HaloPlex HS Target Enrichment System for the Ion 
Torrent sequencing protocol, used for the first gene panel (Version C1, December 
2016) (Figure 3A), was optimized for the digestion of 50 ng of genomic DNA splitted 
among 8 different restriction digestion reactions. The custom HaloPlex HS probes were 
designed through Agilent’s SureDesign tool (www.agilent.com/genomics/suredesign).  
Similarly, HaloPlex Target Enrichment System for the Ion Torrent sequencing protocol 
was also used for the second gene panel (Version E1, July 2015) (Figure 3B). The 
custom HaloPlex probes were designed through the above mentioned Agilent’s 
SureDesign tool.  
The third custom panel was designed through the Ion AmpliSeq™ Designer Tool 
(https://www.ampliseq.com/) that allows simultaneous multiplexed PCR amplification 
of thousands of genomic target regions in 2-Pool panel (Revision A.0, May 2017) 
(Figure 3C). This latter set of genes was ordered through the on demand procedure 
that guarantee optimized conditions of use, as each gene is pre-manufactured, tested 
and verified, allowing to build custom panels from over 5,000 pretested genes that are 
most relevant in the research of inherited germline diseases (e.g. hereditary cancer, 
primary immunodeficiency, hearing loss, muscular dystrophy). The genes not available 
in the on demand offer were synthesized through the Spike-in system, used to extend 
the target range to be sequenced.20  
In each case, a list of candidate genes was submitted to the corresponding online 
software, with the request to design primers able to capture the coding and splice-site 
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For each panel, missed regions in targeted genes were covered by Sanger sequencing. 
Amplicon libraries have been obtained from each DNA sample according to the 
C
  A C
  A 
Figure 3: workflows to prepare samples to 
undergo A. HaloPlex HS target-enriched 
sequencing; B. HaloPlex target-enriched 
sequencing; C. Ion Ampliseq LibraryKit Plus  
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protocol specific to each corresponding gene panel. Whatever the initial capture 
protocol, sample libraries sequencing was carried out through the Ion Torrent™ 
Personal Genome Machine™ (PGM) System. Ion semiconductor sequencing utilizes the 
release of hydrogen ions during the sequencing reaction to detect the sequence of a 
cluster. Each cluster is located directly above a semiconductor transistor which is 
capable of detecting changes in the pH of the solution. Therefore, during nucleotide 
incorporation, a single H+ is released into the solution and it is detected by the 
semiconductor (Figure 4).  
 
 
Figure 4. Step one: when a nucleotide is incorporated into a strand of DNA by a polymerase, a hydrogen ion is 
released as a product. Step two: Ion TorrentTM uses a high-density array of micro-machined wells to perform this 
biochemical process in a massively parallel way; each well holds a different DNA template; beneath the wells is an 
ion-sensitive layer and beneath that a proprietary ion sensor. Step three: when a nucleotide is added to a DNA 
template and is then incorporated into a strand of DNA, a hydrogen ion will be released: the charge from that ion 
will change the pH of the solution, which can be detected by the ion sensor. Step four: PGM sequencer then 
sequentially floods the chip with one nucleotide after another. 
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3.3 Bioinformatic analysis and Sanger validation  
 
Raw data, in FastQ format, were analyzed by the Ion Reporter 5.0 
(https://ionreporter.thermofisher.com/ir/). The total variants were filtered based on 
their frequency in the general population, as reported in the 1000 Genomes 
(http://www.internationalgenome.org) and Exome Aggregation Consortium (ExAC; 
http://exac.broadinstitute.org/) databases. Variants were assessed by the Ion 
ReporterTM Software 5.0 and a custom bioinformatics pipeline was additionally 
optimized to filter-in significant variants. In particular, variants were selected based on 
their frequency in the general population (lower than 5% or unreported), impact on 
the encoded protein (missense, stop loss and stop gain, frameshift, and splicing 
variants at ±2bp from the exon ends), and prediction of functional effects through in 
silico analysis using different online softwares, such as those available at 
https://www.varsome.org; https://www.ensembl.org/info/docs/tools/vep/index.html; 
https://www.ncbi.nlm.nih.gov/clinvar/; https://www.ncbi.nlm.nih.gov/projects/SNP/, 
as well as previous pathogenicity classification at 
http://genetics.bwh.harvard.edu/pph2/; http://sift.bii.a-star.edu.sg/; 
http://www.mutationtaster.org/; https://cadd.gs.washington.edu/.  
Variants thus selected were assessed on the basis of the clinical phenotype of 
probands and validate by standard Sanger sequencing whenever unreported or 
reported as potentially damaging/damaging. To confirm the presence of the selected 
variants, new primers were designed by the Primer3Plus online tool 
(https://primer3plus.com/) and a PCR protocol was set up for each variant. PCR 
products were purified by ExoSAP-OT (GE Healthcare) and directly sequenced by using 
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Big Dye V.1.1 through an ABI3130 automated sequencer (Applied Biosystems, Foster 
City, California, USA). Once validated, variants segregation was finally checked in 
parents, when available (Figure 5). 
 
 









3.4 Western Blot  
 
B lymphocytes from four patients with variants in CASP10 gene were immortalized 
with the Epstein Barr virus according to the Miller protocol (1982).21 Cell lines thus 
obtained were grown in culture medium Roswell Park Memorial Institute (RPMI) with 
antibiotics, glutamine and fetal bovine serum. The cells were then treated or not with 
TNF-related apoptosis-inducing ligand (TRAIL) to induce apoptosis. In parallel, a cell 
line from a healthy donor was treated in the same way to be used as a control. After 4 
hours of treatment, cells were collected, washed and treated with a lysing solution for 
the production of a protein extract. For each cellular extract, proteins were quantified 
and equal amounts were loaded on an acrylamide gel and subjected to electrophoretic 
run. The proteins thus separated were transferred onto a membrane of nitrocellulose 
and those of interest, namely PARP-1, CASP-8, CASP-10, CASP-3 and actin, were 
detected with specific antibodies. Assessment of cell death rates was performed within 
24 hours of the TRAIL treatment, quantifying by cytofluorimetry the number of dead 
cells after staining with propidium iodide.  
 
3.5 Plasmid generation and transfection 
 
Three PIK3CD cDNA clones were purchased from TwinHelix (www.twinhelix.eu), one to 
be used as control carrying the reference sequence while the two other clones carried 
the PIK3CD variants found in patients ID 10 and ID 2391, p.His273Tyr and p.Ser312Cys 
respectively. The reference sequence (NM_005026) was optimized by the company to 
improve its clonability. All the cDNA sequences were cloned into the pcDNA 3.1 vector 
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and fused in frame with C-Myc. Constructs were transferred to the HIT Competent 
Cells through Non-heat Shock Transformation (RBC Bioscence Corp, UK) and plasmid 
DNA was then extracted, after overnight growth in selective medium, through QIAprep 
Spin Miniprep Kit (Qiagen). A digestion with the BamHI and HindIII restriction enzymes 
was carried out to check the plasmid DNAs. cDNA construct DNAs were then used to 
transiently transfect a lymphoblastoid cell line with LipofectamineTM, according to the 
manufacturer’s protocol (www.thermofisher.com). The activity of 
hyperphosphorylation of downstream proteins (AKT-mTOR pathway) was controlled by 























4.1 Gene panel 1  
 
4.1.1 Technical results 
The first gene panel was composed of 146 genes (Table 1). The run metrics for 8 
runs/51 samples using the HaloPlex HS Target Enrichment System protocol are 
summarized in Table 2. The total target region was represented by amplicons with an 
average length of 206 bases, including 337.24kbp designed out of 341.07kbp input 
sequence, namely all the target exons each accompanied by 10 bases of flanking 
regions. Therefore the target representativeness in each library undergoing NGS 
sequencing was 337.24/341.07 => 98.88% (see Appendix 1). 
 
Table 1: list of genes included in the first panel 
 
Table 2: run metrics panel 1 (51 samples, 8 runs). In grey the details per chips, in white the average 
details among all the samples.  
 
*Details available only for 5 runs on 8. 
AID AIRE AK2 AP3B1 ATM BCL10 BLM BLOC1S6 BTK C16ORF57
CARD11 CASP10 CASP8 CD19 CD20 CD21 CD27 CD3D CD3E CD3G
CD40 CD40LG CD81 CD8A CECR1 CORO1A CSF3R CTC1 CTLA4 CTPS1
CXCR4 CYBA CYBB DCLRE1C DKC1 DOCK2 DOCK8 ELA2 EXTL3 FADD
FAS FASLG FOXN1 FOXP3 G6PC GATA2 GFI1 HAX1 HOIP ICOS
IKBKB IL10 IL10RA IL10RB IL21 IL21R IL2RA IL2RG IL7R ITCH
ITK JAGN1 JAK3 KRAS LAMTOR2 LCK LIG4 LRBA LYST MAGT1
MALT1 MAP3K14 MPL NBN NCF1 NCF2 NCF4 NEMO NFKB2 NHEJ1
NOLA2 NOLA3 NRAS ORAI1 OX40 PGM3 PIK3CD PIK3R1 PLCG2 PNP
PRF1 PRKCD PTPRC RAB27A RAC2 RAG1 RAG2 RBCK1 RFX5 RFXANK
RFXAP RPL11 RPL26 RPL35A RPL5 RPS10 RPS17 RPS19 RPS24 RPS26
RPS7 RTEL RUNX1 SBDS SH2D1A SLC37A4 SLC7A7 SMARCAL1STAT1 STAT3
STAT5B STIM1 STK4 STX11 TACI TAP1 TAP2 TAPBP TAZ TBX1
TERT TINF2 TNFRSF13CTPP2 TWEAK TYK2 UNC119 UNC13D UNG VPS13B



















Median 81% 2823353 98 51695122 159 361531 91,17 65,77 77,45
Min 68% 1913494 91 4053953 131 22900 86,8 4,249 65,14
Max 93% 3746411 99 339587222 179 2003927 92,94 370,59 83,39
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4.1.2 Cohort of patients 
Fifty-one patients, already undergone conventional clinical evaluations but without a 
genetic confirmation of the possible diagnosis, were analyzed for the first set of genes. 
They were 25 male and 26 female. The average age at the time of analysis was 15.6 
years. Thirteen had already undergone Sanger sequencing for at least one gene. These 
patients came to our attention as their clinics could be classified into one of five 
categories: Neutropenia diasease (n=4), Immunodeficiency (n=1), Lymphohistiocytosis 
HLH disease (n=1), Bone marrow failure (n=7) and ALPS-like disease (n=38).  
 
4.1.3 Variants 
Table 3 shows a summary of the genetic results thus obtained. On average, 641 
variants were called for each sample. Different filters were applied to assess the 
variants significance. First, only exonic and splice-site variants were filter out. Excluding 
synonymous variants, in the coding regions only missense, stoploss, stopgain, and 
frameshift mutations were considered further. The third filter concerned the 
frequency and the predicted effect of the variants. Annotation was achieved through 
the use of the major databases of known variants dbSNPv.144, ClinVar, 1000Genome 
Browser, Varsome, VEP, and the prediction scores calculated by Polyphen‐2, SIFT, 
Mutation Taster2, and CADD. On average, 14 variants were still deserving 
consideration after the filters applied, and only those believed to contribute to the 
phenotype were validated by Sanger sequencing and reported afterward, i.e. those 
affecting genes already known to be involved in the patients’ respective phenotype.  
Fifteen patients turned out to carry pathogenic variants that correlate with the 
respective clinical phenotype. In particular, five patients (IDs 5, 6, 22, 23, 53) carried 
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five heterozygous pathogenic variants of TNFRSF13B (two alleles p.Arg202His, one 
allele p.Cys104Arg, one allele p.Gln57His, and one allele p.Cys193Ter were detected),22 
each inherited by one of the parents. Each of these patients is affected by Common 
Variable Immunodeficiency (CVID) and the symptoms are autoimmune cytopenia, 
lymphoproliferation, hypogammaglobulinemia, susceptibility to infections, failure to 
respond to vaccinations. Four patients (IDs 11, 12, 30, 38) were found to be 
heterozygous for the p.His159Tyr missense variant in the TNFRSF13C gene (ID 38 
presented a complex allele with a p.Pro21Arg in cis variant inherited by father).23 The 
symptoms reported are autoimmune cytopenia, lymphoprolipheration and failure to 
respond to vaccinations. ID 2 carried a de novo PRKCD variant (p.Gly248Ser) and this 
correlates with the ALPS-like phenotype. Another patient (ID 32) was likely a 
compound heterozygous for 2 ADA2 variants (p.[Thr187Pro];[Leu188Pro]) (the father’s 
DNA was not available, unfortunately, and the mother carried only one of the two 
variants) presenting a phenotype consistent with ADA2deficiency. Two patients were 
homozygous for gene variants responsible of autosomal recessive disorders: ID 39 
carried two LRBA p.Arg655Ter alleles,24 associated with autoimmune enteropathy, 
hypogammaglobulinemia, lymphoprolipheration, autoimmunity, and autoimmune 
hepatitis, while ID 15 carried two RAG1 p.Arg507Gln alleles and presented with 
immunodeficiency, susceptibility to infections, autoimmune cytopenia, Autoimmune 
Hemolytic Anemia (AEA), neutropenia, and thrombocytopenia. In each case, both 
parents were asymptomatic heterozygotes for the corresponding alleles.25 ID 35 
carried a frameshift mutation (p.Cys58fs) in the CTLA4 gene, and this consistently 
correlated with autoimmune cytopenia, AEA, arthritis, lymphoprolipheration, and 
hypogammaglobulinemia. Lastly, one patient (ID 51) carried a splice-site variant in the 
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ELANE gene (c.597+1G>A) that led to severe congenital neutropenia. 
Four patients carried variants of uncertain significance (IDs 19, 24, 40, 45) in genes 
related to their respective clinical phenotypes. For two probands (IDs 24, 45) a 
functional test on the activity of CASP10 was performed due to clinics evocative for 
ALPS/ALPS-like (see below: Western Blot results).  
In the remaining 32 patients we could detect 1) rare variants of uncertain 
significance/probably damaging but not related to their phenotype, 2) rare 
heterozygous variants in autosomal recessive genes or 3) absence of any significant 
variant. One of these patients (ID 9), lacking significant genetic variants, presented 
with such a complex phenotype that prompted us to perform Whole Exome 
Sequencing (data not available). 
 

















2 2003 631 11 PRKCD p.Gly248Ser rs144320413 de novo   
3 2003 746 36 RNF31 p.Glu771Lys rs142436858     
4 2006 697 10 ADA2 p.Met309Ile rs146597836 F   
5 2013 720 18 TNFRSF13B p.Arg202His rs104894649 M 
MPL via 
Sanger  
6 1998 592 17 TNFRSF13B p.Cys104Arg rs34557412 M   
7 1993 657 11         
8 1998 714 13 














11 2011 673 10 TNFRSF13C p.His159Tyr rs61756766   
MVK via 
Sanger 
















14 2000 571 15 RAC2 p.Arg68Gln na     
15 2009 516 16 RAG1 p.Arg507Gln HOMO rs143969029  M, F   
17 2006 654 27 RAG1 p.Asp887Asn rs4151034      





21 2000 758 23 




M WT;  
M (F na) 
  
22 1995 528 12 TNFRSF13B p.Cys193Ter  rs72553885 F   
23 2001 601 20 TNFRSF13B p.Arg202His rs104894649 F   




26 2008 620 23 






    
27 2010 532 13         
28 2009 819 5 CD19 p.Leu285Pro rs764208673      




30 2009 782 19 TNFRSF13C p.His159Tyr rs61756766     
32 1990 594 11 
STAT3 p.Lys658Arg 
(mosaicism);  






M WT;  
 
M;  
M WT (F na) 
  
33 1994 700 14 ADA2 p.Met243Val rs1355940322  F   
34 1993 617 18       
TERC via 
Sanger 
35 1996 640 13 












37 2004 602 14         













39 2009 661 8 LRBA p.Arg655Ter HOMO rs199750191 M, F   
40 2013 534 13 CARD11 p.Arg967Cys rs149857605 M   
41 1998 622 15       
TERC via 
Sanger 
42 2003 555 16 CD19 p.Met16Thr rs745681190      
44 2005 648 10         







46 2006 601 9         
47 2005 622 9 ATM p.Lys1964Glu rs201963507     
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48 1999 594 11 LYST p.Arg2624Trp rs150306354 M 
 
49 2010 584 16 SLC7A7 p.Ala91Val rs11568438     
50 1986 599 11       
HAX1, 
G6PC3 and 
exon 9 of 
WAS via 
Sanger 
51 1987 655 11 ELANE c.597+1 rs878855318     
52 na 600 12         
53 2013 570 14 TNFRSF13B p.Gln57His rs149084717 M 
FAS via 
Sanger 
55 2002 730 16 ADA2 p.Lys481Asn na     




61 2004 666 10 TNFRSF4 p.Arg10Cys rs35304565     
62 2007 690 17 




    
65 2004 745 9         





    
  MEAN 641 14         
*Filtered variants: location: exonic and splicesite; function: missense, frameshift, stoploss, stopgain; 
frequency: MAF≤0.05 and EMAF≤0.05. ** Variants: only validated (true positive) variants are reported; 
variants not validated (false positive) are not reported. *** Parental segregation: F= father; M = mother; 
na = not available 
 
 
4.2 Gene panel 2  
 
4.2.1 Technical results  
The second gene panel was composed of 315 genes (Table 4). The run metrics for 13 
runs/69 samples using the HaloPlex Target Enrichment System protocol are 
summarized in Table 5. The target regions was represented by amplicons with an 
average length of 207 bases, included 750.99kbp designed out of 769.99kbp input 
sequence, namely all the target exons each accompanied by 10 bases flanking regions. 
Therefore the target representativeness in each library undergoing NGS sequencing 




A20 ACP5 ACT1 ACTB ADAR1 AICDA AIRE AK2 AK2 AP1S3
AP3B1 APOL1 ARPC1b ATM BCL10 BLM BLNK BLOC1S6 BOD1L1 BRCA2
BRCA1 BRIP1 BTK C1NH C1QA C1QB C1QC C1R C1S C2
C3 C4A C4B C5 C6 C7 C8A C8B C8G C9
CARD11 CARD14 CARD9 CASP10 CASP8 CD19 CD20 CD21 CD27 CD3D
CD3E CD3G CD3Z CD40 CD40LG CD46 CD59 CD70 CD79A CD79B
CD81 CD8A CEBPE CECR1 CENPS CENPX CFB CFD CFH CFHR1
CFHR3 CFI CFP CHD7 CIITA COLEC11 COPA CORO1A CSF2RA CSF3R
CTC1 CTLA4 CTPS1 CTSC CXCR4 CYBA CYBB DCLRE1C DKC1 DNASE1
DNASE1L3 DNASE2 DNMT3B DOCK2 DOCK8 ELANE ERCC4 EVER1 EVER2 EXTL3
FAAP100 FAAP20 FAAP24 FADD FAN1 FANCA FANCB FANCC FANCD2 FANCE
FANCF FANCG FANCI FANCL FANCM FAS FASLG FCN3 FOXN1 FOXP3
FPR1 FUCT1 G6PC G6PC3 GATA2 GFI1 GIMAP5 HAX1 HOIP ICOS
IFIH1 IFNGR1 IFNGR2 IGLL1 IKAROS IKBA IKBKB IKBKG IKZF1 IL10
IL10RA IL10RB IL12B IL12RB1 IL17F IL17RA IL1RN IL21 IL21R IL2RA
IL2RG IL36RN IL7R IRAK4 IRF8 IRF8 ISG15 ITCH ITGB2 ITK
JAGN1 JAK1 JAK3 KIND3 KRAS LACC1 LAMTOR2 LCK LIG4 LPIN2
LRBA LYST MAGT1 MALT1 MAP3K14 MASP1 MASP2 MCM4 MDA5 MEFV
MPL MRE11 MTHFD1 MVK MYD88 NBN NCF1 NCF2 NCF4 NFKB2
NFKBID NHEJ1 NLRC4 NLRP12 NLRP3 NLRP7 NOD2 NOLA2 NOLA3 NRAS 
ORAI1 OTULIN OX40 PALB2 PAX5 PGM3 PI3K PIK3CD PIK3R1 PLCG2
PMS2 PNP POLE1 PRF1 PRF1 PRKCD PSMA3 PSMB4 PSMB8 PSMB9
PSTPIP1 PTPRC RAB27A RAC2 RAD51 RAD51C RAG1 RAG2 RASGRP1 RBCK1
RFX5 RFXANK RFXAP RHOH RNASEH2A RNASEH2B RNASEH2C RNF168 RPL11 RPL26
RPL35A RPL5 RPS10 RPS17 RPS19 RPS24 RPS26 RPS7 RPSA RTEL1
RUNX1 SAMHD1 SBDS SEMA3E SERPING1 SH2D1A SH3BP2 SLC29A3 SLC37A4 SLC46A1
SLC7A7 SLX4 SMARCAL1 SP110 SPINK5 STAT1 STAT2 STAT3 STAT5B STIM1
STK4 STN1 STX11 STXBP2 STXBP2 TAP1 TAP2 TAPBP TAZ TBK1
TBX1 TCF3 TCF3 TCN2 TERT THBD TINF2 TLR3 TMEM173 TNFAIP3
TNFRSF11A TNFRSF13B TNFRSF13C TNFRSF1A TPP2 TRAF3 TREX1 TRIF TTC7A TWEAK
TYK2 UAF1 UBE2T UNC119 UNC13D UNC93B1 UNG USB1 USP1 VPS13B
VPS45 WAS WIPF1 WRAP53 WDR1 XIAP ZAP70 ZBTB24
Table 4: list of second panel of genes 
 
 













Table 5: run metrics panel 2 (63 samples, 13 runs). In grey the details per chips, in white the average 
details among all the samples. 
 
 
4.2.2 Cohort of patients  
Sixty-nine patients, already undergone conventional clinical evaluations but without a 
genetic confirmation of the possible diagnosis, were analyzed for this second set of 



















Median 85 3306935 99,7 88714997 172 521507 97,42 42,73 75,18
Min 70 484336 99,4 1674265 122 10615 94,13 0,874 41,17
Max 94 5785648 99,8 225595060 198 1231245 98,91 110,1 99,71
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14 years. Twenty-four had already undergone Sanger sequencing for at least one gene 
and, in particular, 5 of these had also been analyzed for a custom panel of genes 
specific for auto-inflammatory disorders (2 for a 41 gene panel, 3 for a 11 gene panel). 
The 69 patients belonging to this second set came to our attention as their clinics could 
be classified into two categories: ALPS and ALPS-like disease (n=40), Bone marrow 
failure (n=10), Autoinflammatory disease (n=12), complement disease (n=1) and 
immunodeficiency (n=6) 
 
4.2.3 Variants  
Table 6 shows a summary of the genetic results thus obtained. The mean 
coverage/sample was 164,59X. On average, 1413 variants were called for each sample. 
After applying the filters previously described,  an of average 25 variants per sample 
was obtained. Only those variants believed to contribute to the phenotype were 
validated by Sanger sequencing and reported afterward. Sixteen patients turned out to 
carry pathogenic variants that correlate with the respective clinical phenotype. Four of 
them (IDs 88, 100, 114 and 120) carried pathogenic heterozygous variants of 
TNFRSF13B (p.Cys104Tyr; p.Glu117fs; p.Leu69fs; p.Ser194Ter). Only the p.Glu117fs 
could be assessed in family members and transmission found from the father. Each of 
these is affected by Common Variable Immunodeficiency (CVID) showing symptoms 
such as autoimmune cytopenia, lymphoproliferation, hypogammaglobulinemia, 
susceptibility to infections, failure to respond to vaccinations. ID 38, run also in the 
previous panel, confirmed the already detected TNFRSF13C variants and nothing else 
of significant meaning came out. Another patient (ID 1176) was a compound 
heterozygous for 2 MVK variants (p.[Leu168_Asp170delinsHis];[Val377Ile]), presenting 
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with a Hyper-IgD Syndrome. One male (ID 80) was hemizygous for a X-linked IKBKG 
variant, inherited by the asymptomatic mother, with typical ALPS symptoms. ID 97 was 
homozygous for IL7R gene variants responsible for an autosomal recessive disorder 
(OMIM #608971: Severe Combined Immuno Deficiency). ID 2391 and ID 111 presented 
the same mutation in the PIK3CD gene of ID 16 for whom direct Sanger sequencing for 
PIK3CD gene was performed in our lab. A functional test on the activity of PIK3CD was 
performed also for ID 10 (see plasmid results below). They suffer from Activated PI3K-
delta Syndrome (APDS), characterized by onset of recurrent sinopulmonary and other 
infections in early childhood. ID 109, ID 131, ID 145 and ID 64, presented variants in 
TMEM173, STAT3, CASP10, and RPS19 genes, respectively, already shown pathogenic 
in literature, even through functional studies, and leading to consistent corresponding 
clinic phenotypes.26-29 In particular, STING-associated vasculopathy with onset in 
infancy (SAVI) is caused by TMEM173 mutation; STAT3 leads to autoimmune 
thrombocytopenia, lymphoprolipheration ALPS-like; ID 145 presents a typical ALPS 
phenotype caused by CASP10 mutation; RPS19 conduce to Anemia of Blackfan 
Diamond with typical clinic. 
ID 90 and ID 92 carried a stopgain variant in the NHEJ1 gene and a missense variant in 
the CTLA4 gene, respectively, both unreported so far. ID 90 shows AEA but without 
signs of bone marrow failure or dysmorphic features; ID 92 exhibits a phenotype 
consistent with his genotype, including autoimmune enteropathy, autoimmune 
cytopenia, hypogammaglobulinemia, and lymphoprolipheration.  
Six patients carried variants of uncertain significance (IDs 10, 58, 94, 110, 113, 2130) in 
genes related to their respective clinical phenotypes. In the remaining 49 patients we 
could detect 1) rare variants of uncertain significance/probably damaging but not 
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related to their phenotype, 2) rare heterozygous variants in autosomal recessive genes 
or 3) absence of any significant variant. 
 


















10 2014 82,68 1335 21 
PIK3CD p.His273Tyr;   





F;   
M;  
M  
25 2005 231,25 1811 18       










54 2005 244,66 1924 21       
58 1991 262,63 1031 23 












63 2010 95,24 1407 28       
64 2011 237,86 1928 33 RPS19 p.Arg62Trp rs104894711   
71 1996 312,92 1762 28 RAG2 p.Gly509Asp rs779267024   
72 2002 317,41 1944 22       








75 2006 123,84 718 12 RAG1 p.Gln407Glu  na M 
80 1992 183,09 1225 14 
IKBKG p.Glu125Lys 
HEMIZYGOUS 
rs148695964  M 
81 2004 240,29 1842 21       
82 2001 27,44 914 30 FANCA p.Ala628Thr rs766422868   
84 2009 182,72 750 24 
IFIH1 p.Arg186Cys; 




rs886048934   
85 2010 30,29 1019 35       
86 2006 95,55 1470 21 
C8B p.Arg428Ter;  
FANCG p.Asp362Gly;  







87 2000 320,76 1827 21 
AIRE p.Arg356Trp;  










rs754033733   
90 2016 155,91 1105 16 
CXCR4 p.Leu125Val;  
NHEJ1 p.Arg57Ter 
rs1001278766; 
rs118204451   
92 2017 147,97 1196 18 
CTLA4 p.Leu180Pro;  








94 2000 170,57 1292 22 
NCF1 p.Phe275Phe;  
NCF1 p.Ala308Val 
na;  
na   
97 2016 189,83 815 28 IL7R p.Cys118Tyr HOMO rs193922641    
41 
 
99 2008 147,79 1744         
100 1989 175,37 1614 22 









102 1998 343,89 1961 34 















105 2008 125,85 1517 26 
AIRE p.Arg9Trp;  
AIRE p.Val484Met 
na; 
rs367966318   
106 2000 20,54 703 25 RNASEH2B p.Ala177Thr rs75184679    
109 2013 209,88 1603 26 TMEM173 p.Val155Met na   
110 1993 235,65 1349 16 
NLRC4 p.Arg492Trp; STAT5B 
p.Arg100Cys 
rs1317272776; 
rs199894785   
111 2015 197,66 1870 28 PIK3CD p.Ser312Cys  rs61755420   
112 2008 169,25 1039 19 RAG1 p.Asn968Lys rs193922463   
113 2002 179,23 1780 35 CASP8 p.Arg494Ter rs1368296717   
114 na 145,43 1123 10 TNFRSF13B p.Leu69fs rs72553875   
116 1989 131,77 816 12       
117 2013 152,04 1785 32       






124 2009 91,23 1443 19 






126 2005 89,58 1549 32 CASP8 p.Val31Glu na   
127 2016 69,35 953 22       
128 1994 87,02 1505 39       
129 2013 101,59 1158 26 TINF2 p.Pro214Ser rs372610524   
130 2004 102,07 1507 18 PRF1 p.Asn252Ser     
131 2006 100 1450 25 STAT3 p.Arg152Trp rs869312890   
132 2003 115,9 1607 23 C1S p.Arg534Trp rs121909582   
133 1990 125,3 1613 20       
134 2002 137,58 1391 30       
135 2014 60,64 1095 28 SH3BP2 p.Thr531Ile rs746860671   
144 2013 102,01 1011 27 IL21R p.Pro220Leu rs780311714   
145 2006 125,39 743 32 
TMEM173 p.Ala97Thr; 
TMEM173 p.Ala21Thr;  







146 2004 167,81 942 17       
1030 2001 179,78 1656 21       








1461 2002 144,57 1565 29       
1704 1998 106,46 1242 23       
1838 2000 150,19 1701 26 NFKBID p.Pro258Leu rs748957539   
1980 2003 77,57 932 21       
2060 2006 136,77 1721 23       
2300 2002 232,15 1834 16       
42 
 
2130 na 245,27 1590 35 






2391 1999 353,35 1860 25 PIK3CD p.Ser312Cys rs61755420 F 
2421 1989 74,85 1017 25       
2584 2001 61,89 1462 26       
2724 1998 143,59 1517 31 TBK1 p.Leu508Ile rs144424516   
2746 2000 246,19 1694 25       
2802 1999 306,77 1729 32  LPIN2 p.Ala331Ser  rs80338805   
2582 1991 206,10 1703 34 STXBP2 p.Ile74Phe na   
2896 2000 236,98 1810 26 GATA2 p.Ala286Pro rs775661802   
 
MEAN 164.59 1413 25 
     
*Filtered variants: location: exonic and splicesite; function: missense, frameshift, stoploss, stopgain; 
frequency: MAF≤0.05 and EMAF≤0.05. ** Variants: only validated (true positive) variants are reported; 
variants not validated (false positive) are not reported. *** Parental segregation: F = father; M = 






4.3 Gene panel 3  
 
4.3.1 Technical results  
The third gene panel was composed of 58 genes (Table 7). The run metrics for 3 run/30 
samples using the Ion Ampliseq Library Kit Plus protocol are summarized in Table 8. 
The target region was covered by a total of 1035 amplicons (average length 202 bases) 
including 197.35 kbp designed out of 209.54 kbp of the input, namely target 
representativeness in each library undergoing NGS sequencing was 197.35/209.54 => 
94.18% (see Appendix 3).  
 
Table 7: list of third panel of genes 
 
 
Table 8: run metrics panel 3 (30 samples, 3 runs). In grey the details per chips, in white the average 
details among all the samples. 
 
 
4.3.2 Cohort of patients 
Thirty patients, already undergone conventional clinical evaluation but without a 
genetic confirmation of the possible diagnosis, were analyzed for this third set of 
AP3B1 C16orf57 CARD11 CASP10 CASP8 CD19 CD20 CD40 CD40L CSF3R
CTC1 CTLA4 CXCR4 DKC1 ELA2 FADD FAS FASL G6PC GFI1
HAX1 ITK JAGN1 KRAS LAMTOR2 LRBA LYST MAGT1 NHP2 NOP10
NRAS PIK3CD PIK3R1 PRKCD RAB27A RAC2 RPL11 RPL26 RPL35A RPL5
RPS10 RPS17 RPS19 RPS24 RPS26 RPS7 RTEL1 SBDS SLC37A4 TAZ




















Median 87 2550372 99,4 44120544 200 278374 92,45 214,92 97,29
Min 85 684791 99 15053101 171 84965 83,99 69,51 95,45
Max 91 3673701 99,7 114146579 205 1406575 97,3 568,3 97,84
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genes. They were 16 male and 14 female. The average age at the time of analysis was 
14 years. Nine of them had already undergone Sanger sequencing for at least one 
gene. These patients came to our attention as their clinics could be classified into 3 
categories: ALPS-like disease (n=19), Bone marrow failure (n=6), Neutropenia (n=5).  
 
4.3.3 Variants 
Table 9 shows a summary of the results of the third gene panel. The mean 
coverage/sample was 208.30X. On average, 127 variants were called for each sample. 
The filters applied were those previously described , obtaining an average of 4 variants 
to follow-up per sample. Indeed, only those believed to contribute to the phenotype 
were validated by Sanger sequencing and reported afterward. Two patients turned out 
to carry pathogenic variants that correlate with the respective clinical phenotype and 
reported in literature: ID 157 showed a variant in CASP10 (p.Ile406Leu) with typical 
ALPS phenotype while ID 162, studied for bone marrow failure, had a variant in 
TNFRSF13B (p.Cys104Arg) but not presented CVID clinical features. Four patients 
carried variants of uncertain significance (IDs 143, 147, 163, 175) in genes related to 
their respective clinical phenotypes, though variable expressivity led to lack of some 
symptom and limited clinical spectra, like in the case of ID 163 presenting with 
neutropenia but without dysmorphic feature. ID 139 and ID 178 showed the same 
splice-site mutation (c.258+2T>C) in heterozygosity in the SBDS gene, already reported 
as a susceptibility variant to aplastic anemia (OMIM #609135) and inconsistent with 
their ALPS-like phenotype. In the remaining 22 patients we could detect 1) rare 
variants of uncertain significance/probably damaging but not related to their 
phenotype, 2) rare heterozygous variants in autosomal recessive genes or 3) absence 
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of any significant variant. 


















EI139 1996 256,54 174 11 
LYST p.Arg988Gln;  




rs113993993   
EI143 2011 325,67 163 11 






EI147 na 107,24 133 2 WAS p.His180Asn HOMO rs145040665 
WAS via 
Sanger 
EI154 2000 143,83 137 1       
EI155 2015 133,09 124 4       
EI156 2002 69,19 100 4       
EI157 1998 124,97 126 5 
CASP10 p.Ile406Leu; 
CASP8 p.Lys207Arg;  
rs80358239; 
rs148697064   
EI158 2007 162,35 105 2       
EI159 2010 118,54 134 3 G6PC p.Thr267Met;  rs145296477   
EI160 2010 96,14 125 2       
EI161 2013 156,02 125 2       
EI162 2016 152,58 106 4 TNFRSF13B p.Cys104Arg;  rs34557412   




rs142476821   
EI164 1995 129,31 118 3 CASP10 p.Pro501Leu rs148939095   
EI165 1996 123,36 130 5 CTC1 p.Gly414Ala rs62624978   
EI166 2003 118,19 136 4       
EI167 2003 100,16 136 6 
LRBA p.Lys2298Glu;  




EI168 1989 138,00 96 5 WRAP53 p.Gly521Trp rs967111874   
EI169 2012 176,69 111 4       
EI170 1998 158,37 121 3       
EI171 2003 98,37 122 4       
EI172 2002 174,63 133 4 LRBA p.Arg2862Cys rs145709687   
EI173 1991 165,17 137 6 CASP8 p.Lys207Arg rs148697064   
EI174 2007 82,38 134 6 AP3B1 p.Val315Ala na   
EI175 2002 544,50 114 2 TERT p.Gly406Arg rs866101734   
EI176 2001 458,13 134 3 WAS p.Glu131Lys rs146220228   
EI178 2011 500,03 111 5 
FAS p.Thr319Ile;  
SBDS c.258+2T>C 
rs372459755; 
rs113993993   
EI179 2004 483,69 145 6       
EI180 2005 363,85 108 3 USB1 p.Ile171Thr rs149725439   
EI181 na 421,80 144 3       
 
MEDIAN 208,30 127 4 
  
  
*Filtered variants: location: exonic and splicesite; function: missense, frameshift, stoploss, stopgain; 
frequency: MAF≤0.05 and EMAF≤0.05. ** Variants: only validated (true positive) variants are reported; 




4.4 Western Blot results 
 
Among patients enrolled, four (1 males and 3 females) showed different genotypes for 
common variants in CASP10 and CASP8 genes associated with suggestive features of 
definitive/probable ALPS or ALPS-like. Lymphoblastoid cell lines from these four 
patients were used to deepen into the genotype-phenotype correlation, namely on the 
possible involvement of CASP-genes in the development of ALPS and ALPS-like clinics. 
Four hours after cell treatment with TRAIL, Western blot analysis of apoptosis cascade 
proteins showed a lack of cleavage of CASP8 and PARP proteins, supposed to result in 
defective apoptosis, as observed in the positive control/patient ID145 who carries the 
CASP10 mutation p.Ile406Leu, a pathogenic mutation. Consistently, in the same test 
the AHH-1 cell line, used as healthy control, did not show any cleavage defect (Figure 
6). We have also calculated genotype and allele frequency of these variants in our 
cohort (n=149) and found they are in line with the frequencies reported on the ExAC 
Browser (Table 10). 
 








c.1228 G>A p.V410I 133 GG (0,89) 16 GA (0,11) 0 AA (0) 282 G (0,95) 16 A (0,05) 0,04
c.1337 A>G p.Y446I 142 AA (0,95) 7 AG (0,05) 0 GG (0) 291 A (0,98) 7 G (0,02) 0,03
c.1564 T>A p.L522I 59 TT (0,40) 59 TA (0,40) 31 AA (0,20) 177 T (0,60) 121 A (0,40) 0,41
c.2 T>C p.M1T 138 TT (0,92) 10 TC (0,07) 1 CC (0,01) 286 T (0,97) 11 C (0,03) 0,04
c.41 A>G p.K14R 24 AA (0,16) 76 AG (0,51) 49 GG (0,33) 124 A (0,42) 174 G (0,58) 0,67
C.1030 G>C p.D344H 118 GG (0,79) 28 GC (0,19) 3 CC (0,02) 264 G (0,89) 34 C (0,11) 0,09





SNP p.V410I GG GG GA GG
SNP p.Y446I AA AA AA AG
SNP p.L522I TA TA TA AA
SNP p.M1T CC TT TT TT
SNP p.K14R GG AG GG GG
SNP p.D344H GG GG GC GC
Figure 6: Western Blot analysis of apoptotic cascade proteins after treatment with TRAIL for 4 patient 
















 AHH-1       ID 145        ID 36           AHH-1        ID 38        ID 24        ID 45 
cell line                                             cell line 
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4.5 Plasmid results 
 
Four PI3KCD gene mutations have been known so far to impair T and B-cells 
homeostasis through an AKT-mediated hyperactivation of mTOR (OMIM #602839: 
p.Glu1021Lys, p.Asn334Lys, p.Glu525Lys, p.Cys416Arg). This causes APDS 
characterized by impaired immunoglobulin production, respiratory infections, 
gut/pulmonary infiltrates, and lymphoproliferation.30 Among others, here we describe 
two patients harboring two novel PI3KCD mutations whose dominant clinical feature is 
the erythroid and myeloid precursors Marrow Failure (MF), respectively. Therefore, 
the activity of hyperphosphorylation of downstream proteins (AKT-mTOR pathway) 
has been checked by Western Blot in in vitro transfected samples (Figure 7). Data show 
an increase in protein phosphorylation in the PI3K/AKT/mTOR pathway for the plasmid 
carrying the p.S312C (ID 2391) mutation, compared to the wild type and to the plasmid 
carried the p.H273Y (ID 10) mutation. 
 































Primary Immunodeficiency Disorders (PIDs) are clinically heterogeneous disorders that 
arise from genetic defects in genes involved in immunity. The clinical effects of 
mutations in PID genes extend well beyond susceptibility to infection with bacteria, 
virus and opportunistic organisms. Immune dysregulation phenotype of PID are 
common and include multiorgan autoimmunity, haematological malignancy and 
autoinflammatory conditions. These pathologies can coexist and are often seen in 
combination. Furthermore, different mutations in the same gene can lead to different 
PID presentations, depending on whether the net effect is gain or loss of function at 
the protein level or on the affected domain. Most PIDs have a simple Mendelian 
inheritance and cause symptoms in early life, while adult presentations tend to reflect 
polygenic diseases, such as common variable immunodeficiency disorder (CVID) or 
diseases in which an environmental component reveals the underlying immunological 
phenotype. The wide phenotypic heterogeneity of PIDs, with often blurred and 
overlapping phenotypes between different clinical entities, has been preventing an 
effective genetic definition, including genotype-phenotype correlation, and ultimately 
a diagnostic assessment for many of these disorders. This has prompted us, in 
collaboration with the Hematology Unit and the Rheumatology Unit of IRCCS Istituto 
Giannina Gaslini, to develop and validate different NGS based gene panels for such 
haematological and immunological diseases, exploring the effectiveness and reliability 
of different gene combinations and various protocol options, in patients presenting 
with tricky phenotypes.  
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Given the possibility to investigate multiple genes at the same time, the advent of NGS 
has revolutionized clinical immunology, by allowing detailed characterization of the 
genetic architecture of the immune system in patients with significant and complex 
immunological defects, increasing our knowledge on the pathogenesis of these genetic 













Figure 8: genomic architecture of the immune system (from Shields and Patel 2017).
 
 
In this study, we used NGS technologies to identify potential disease-causing 
mutations in patients affected with clinical phenotypes highly suggestive of PID, many 
of them yet undiagnosed after using traditional Sanger sequencing protocol, and to 
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genetically define the overlap between the different disorders. Some cases might 
represent phenotypic expansion of a known disorder to include immunodeficiency. For 
some autosomal dominant traits, we noted reduced penetrance associated with 
variant alleles, while for some autosomal recessive traits, we found predisposing 
variants in outbred populations. Technically, the procedure has excellent performance 
in evaluating large genes, features the possibility to screen up tents of patients in a 
single run (i.e. 22 patients for the third panel, the smallest) and its versatility allows the 
gene panel to be updated timeliness, depending on the selected cohorts and the new 
genes discovered, as we could experience in these latest three years. 
One key difficulty in the design of these panels is defining the appropriate list of genes 
for a given phenotype because of the remarkable variability in clinical presentations. If 
a panel is designed to focus on certain PID phenotypes, there is a high probability that 
atypical presentations will be missed. On the other hand, a larger panel can lead to 
identify variants never seen before and / or in genes that are still little known. 
 
Results achieved in the present study illustrate the effectiveness of the assays 
developed for detecting point mutations in known PID genes. The mutation rates of 
these panels were 15/51 (29%), 16/68 (23%) and 2/30 (6%) from the first to the third 
ones, respectively. The disorders that had a more accurate diagnosis were ALPS/ALPS-
like (13/15; 12/16; 1/2), followed by BMF (1/15; 1/16; 1/2). Lastly, one diagnosis for 
neutropenia (panel 1), one for immune-deficiency and two for autoinflammatory 
diseases (panel 2) were also made. Albeit with different efficiencies, most of the 
clinical categories included in the study had a genetic diagnosis among the sequenced 
genes. The demand for NGS-based testing has grown rapidly without a corresponding 
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increase in the rate of detection of causative mutations, a circumstance that has had a 
strong impact on the yield of NGS panels, in terms of the proportion of patients that 
have been diagnosed through the molecular approach. Indeed, in the literature, the 
yield of the most focused disease panels varies from a higher yield (40–50%) to a lower 
yield (15–25%), likely depending on the phenotype and genetic heterogeneity of the 
included disorders, as well as, for recessive diseases, on the level of consanguinity of 
parents (correlated to the degree of inbreeding of the populations which patients 
belong to). For instance, different targeted gene panels for PID including between 162 
and 173 genes allowed a definitive diagnosis in 15–25% in a total of 285 patients,10,12,13 
while the diagnostic yield was much more heterogeneous in patients with epilepsy 
ranging from 10 to 48.5% using panels including from 35 to 265 genes.31 
 
As also reflected in the literature, in this study variants of unknown significance in 
potentially causative genes were found in 14 patients (4/51; 4/69; 6/30). For some of 
these, we attempted to study the effect of the variant through functional tests and to 
classify them all.  
Excluding ALPS-related disorders with known genetic mutations, our clinical 
hematologists arbitrarily considered ALPS-like, and addressed to the genetic analysis 
all the conditions in which patients had symptoms and laboratory alterations similar to 
ALPS patients, with no definitive characterization and/or incomplete diagnosis, 
according to 2009 NIH revised diagnostic criteria.32 Indeed, our preliminary study 
shows that all the CASP10 gene variants observed, even known as polymorphic or 
uncertain, similarly to mutations already established as pathogenic and regardless of 
the clinical phenotype, when tested by Western Blot resulted in defective cleavage of 
54 
 
CASP8 and PARP proteins. This contradictory observation may be explained by 
hypothesizing that specific CASP10 mutations have an incomplete penetrance, and/or 
possible epistatic effects on other genes and/or unknown genetic and epigenetic 
factors that would be infact the primary effectors of FAS-mediated apoptosis.33 
Moreover, the allele frequency of these variants estimated in our affected population 
is identical to the one known for the healthy population: this allows us to conclude 
that these polymorphisms neither predispose to pathology nor do they have a 
protective effect.  
Similarly, we investigated also the variants of the PI3KCD gene found among our 
patients. Patient ID 2391 (and also ID 111) carried the mutation p.S312C of the PI3KCD 
gene. Clinically, presented an acute and very severe Pure Red Cell Aplasia (PRCA) 
characterized by life-threatening haemoglobin levels (2.1 gr/dl), absence of 
retyculocytes, and hepatomegaly. Bone marrow evaluation showed severely reduced 
erythroid precursors at any stage of maturation. The variant is present in this patient 
and in her mother, who had history of severe seizures during childhood but not of 
anemia. The levels of AKT protein phosphorilation tested by Western-blot has been 
found increased compared to an age-matched healthy control. PI3Kδ protein is broadly 
expressed in mice brain but its role in human nervous system is still unclear, although 
neurological symptoms (autism and neurodevelopmental delay) were reported in 
APDS patients.28 Based on these observations and on the known APDS clinical 
heterogeneity within family members carrying the same mutation, we are tempted to 
speculate that both seizures and the severe encephalopathy may also be part of the 
APDS phenotype. Therefore, the p.S312C mutation of the PI3KCD gene may generate a 
so far unreported clinical phenotype of APDS, whose most striking feature is hypo-
55 
 
regenerative cytopenia. This finding widen the spectrum of genetic diseases underlying 
Marrow Failure (MF) in children and highlights the possible overlap between these 
disorders and Combined Immunodeficiencies (CIDs), as reported in other syndromes, 
thus outlining the need to include CID in the differential diagnosis of MF, particularly if 
a single-lineage is involved.  
Patient ID 10 carried the mutation p.H273Y of the PIK3CD gene, which was also found 
in her healthy father. She presented severe neutropenia, mild anemia and 
thrombocytopenia and bone marrow aspirate showed absence of myeloid precursors 
at any stage of maturation and presence of megakaryocytes highlighting features of a 
Pure White Cell Aplasia (PWCA). The levels of AKT protein phosphorilation tested by 
Western-blot has not been found increased compared to an age-matched healthy 
control.  
Our attention was also attracted by the considerable frequency of heterozygous cases 
of RAG1 variants (8/149=5.37%). Three of these fall in the Zinc Binding Domain (Zn-BD) 
(p. Asp887Asn; p.Asn968Lys; p.Ser982Tyr) and two in the Nonamer Binding Domain 
(NBD) (p.Gln407Glu; p.Arg449Lys). In particular, p.Asn968Lys is reported on Clinvar as 
likely pathogenic and is very close to the conserved catalytic amino acid E965, which 
may alter the structure of the catalytic centre and the DNA-binding capability. 
Notarangelo et al collected all the mutations of RAG1 gene and associated them with 
the various possible phenotypes.34 Disease-associated missense mutations have 
predominantly been detected in the Zinc-Binding region of RAG1 core domain; 
however, when normalized to the length of each domain, a higher mutation rate is 
observed in the NBD, followed by the Carboxy-Terminal Domain.34 Our suspicion is 
that some of these variants can have a biological meaning even if in heterozygosis and, 
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for the most evocative cases, there is the possibility of a null allele, which might be 
demonstrated by checking the gene transcript to look for loss of heterozygosity.  
 
Among patients unsolved, as left without a genetic diagnosis, we cannot rule out the 
possibility of novel genetic/clinical entities, our cohort including many atypical cases. 
Indeed, negative cases are likely to be enriched in novel genetic cause of PIDs. 
In the majority of the patients evaluated with the present targeted NGS approach, we 
were not able to find a genetic defect definitively explaining the clinical phenotype, a 
circumstance primarily attributed to the phenotypic and genotypic heterogeneity of 
PIDs. Moreover, the two main technical causes able to account for negative cases 
might be 1) defects in genes not included in our panel because not yet described in 
literature and/or 2) defects located in regulatory regions not sequenced by targeted 
panels. The second-line diagnostic tool, as possible solutions for these unsolved cases, 
might be represented by the use of the Whole Exome Sequencing, covering all the 
existing genes, or the Whole Genome Sequencing, detecting alterations in regulatory 
































The Next Generation Sequencing approach, applied for Primary Immunodeficiency 
Disorders (PIDs), has demonstrated excellent performances in the 1) evaluation of 
large genes and mutation detection, 2) possibility to screen up dozens of patients in a 
single run, despite diseases rarity, 3) overall timeliness of the gene panels, relying on 
continuous literature updates, and 4) definition of different disease clinical entities 
characterized by overlapping phenotypes.  
On the other hand, due to the remarkable variability in clinical presentations, defining 
the appropriate list of genes for a given phenotype represents one key difficulty in the 
design of these panels: a small panel targeted to genes known to be involved in well-
characterized patients may be effective as a primary diagnostic screening test. In our 
experience, however, the best results have been obtained from the widest panels, as 
expected being the Unit of Hematology of Istituto Giannina Gaslini a National referent 
for rare and still genetically undefined hematological diseases. 
Based on the present work, in the near future we need to focus on the functional study 
of the many variants, especially those of uncertain significance, that have emerged in a 
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Appendix 1: list of genes included in panel 1 with proportion of target covered in the design (cover.) 
Target ID  Cover. Target ID  Cover. Target ID  Cover. Target ID  Cover. Target ID  Cover. 
AID 100 CTPS1 100 IL7R 100 PIK3R1 100 SLC7A7 100 
AIRE 100 CXCR4 100 ITCH 100 PLCG2 100 SMARCAL1 100 
AK2 100 CYBA 100 ITK 100 PNP 100 STAT1 100 
AP3B1 100 CYBB 100 JAGN1 100 PRF1 100 STAT3 100 
ATM 100 DCLRE1C 100 JAK3 100 PRKCD 100 STAT5B 90,23 
BCL10 100 DKC1 100 KRAS 100 PTPRC 97,54 STIM1 100 
BLM 100 DOCK2 100 LAMTOR2 100 RAB27A 100 STK4 100 
BLOC1S6 100 DOCK8 100 LCK 100 RAC2 100 STX11 100 
BTK 100 ELA2 100 LIG4 100 RAG1 100 TACI 100 
C16ORF57 100 EXTL3 100 LRBA 99,94 RAG2 100 TAP1 100 
CARD11 100 FADD 100 LYST 99,99 RBCK1 100 TAP2 99,71 
CASP10 100 FAS 100 MAGT1 99,4 RFX5 100 TAPBP 100 
CASP8 100 FASLG 100 MALT1 100 RFXANK 93,94 TAZ 100 
CD19 100 FOXN1 100 MAP3K14 100 RFXAP 100 TBX1 100 
CD20 100 FOXP3 100 MPL 100 RPL11 100 TERT 100 
CD21 100 G6PC 100 NBN 100 RPL26 100 TINF2 100 
CD27 100 GATA2 100 NCF1 42,96 RPL35A 100 TNFRSF13C 100 
CD3D 100 GFI1 100 NCF2 100 RPL5 100 TPP2 100 
CD3E 100 HAX1 100 NCF4 100 RPS10 100 TWEAK 100 
CD3G 100 HOIP 100 NEMO 46,03 RPS17 15,97 TYK2 100 
CD40 100 ICOS 100 NFKB2 100 RPS19 100 UNC119 100 
CD40LG 100 IKBKB 100 NHEJ1 100 RPS24 100 UNC13D 100 
CD81 100 IL10 100 NOLA2 100 RPS26 100 UNG 100 
CD8A 100 IL10RA 100 NOLA3 100 RPS7 100 VPS13B 100 
CECR1 100 IL10RB 100 NRAS 100 RTEL 100 VPS45 100 
CORO1A 95,62 IL21 100 ORAI1 100 RUNX1 99,94 WAS 100 
CSF3R 100 IL21R 100 OX40 100 SBDS 92,88 WIPF1 100 
CTC1 100 IL2RA 100 PGM3 100 SH2D1A 100 WRAP53 100 
CTLA4 100 IL2RG 100 PIK3CD 100 SLC37A4 100 XIAP 100 
  
  






Appendix 2: list of genes included in panel 2 with proportion of target covered in the design (cover.) 
Target 
ID  
Cover. Target ID  Cover. Target ID  Cover. Target ID  Cover. Target ID  Cover. 
A20 99,49 CENPS 100 HAX1 100 NHEJ1 100 SERPING1 100 
ACP5 100 CENPX 100 HOIP 100 NLRC4 100 SH2D1A 100 
ACT1 100 CFB 100 ICOS 100 NLRP12 100 SH3BP2 100 
ACTB 61,77 CFD 100 IFIH1 100 NLRP3 100 SLC29A3 100 
ADAR1 100 CFH 100 IFNGR1 100 NLRP7 99,77 SLC37A4 100 
AICDA 100 CFHR1 95,24 IFNGR2 100 NOD2 100 SLC46A1 100 
AIRE 100 CFHR3 88,54 IGLL1 100 NOLA2 100 SLC7A7 100 
AK2 100 CFI 100 IKAROS 100 NOLA3 100 SLX4 100 
AP1S3 100 CFP 100 IKBA 100 NRAS 100 SMARCAL1 100 
AP3B1 100 CHD7 100 IKBKB 100 ORAI1 100 SP110 100 
APOL1 100 CIITA 100 IKBKG 46,03 OTULIN 100 SPINK5 100 
ARPC1B 100 COLEC11 100 IKZF1 100 OX40 100 STAT1 100 
ATM 100 COPA 100 IL10 100 PALB2 100 STAT2 100 
BCL10 100 CORO1A 95,62 IL10RA 100 PAX5 100 STAT3 100 
BLM 100 CSF2RA 22,43 IL10RB 100 PGM3 100 STAT5B 90,23 
BLNK 99,46 CSF3R 100 IL12B 100 PI3K 99,63 STIM1 100 
BLOC1S6 100 CTC1 100 IL12RB1 100 PIK3CD 100 STK4 100 
BOD1L1 100 CTLA4 100 IL17F 100 PIK3R1 100 STN1 100 
BRCA1 100 CTPS1 100 IL17RA 100 PLCG2 100 STX11 100 
BRCA2 99,97 CTSC 100 IL1RN 100 PMS2 74,9 STXBP2 98,89 
BRIP1 100 CXCR4 100 IL21 100 PNP 100 TAP1 100 
BTK 100 CYBA 100 IL21R 100 POLE1 99,89 TAP2 99,85 
C1NH 100 CYBB 100 IL2RA 100 PRF1 100 TAPBP 100 
C1QA 100 DCLRE1C 100 IL2RG 100 PRKCD 100 TAZ 100 
C1QB 100 DKC1 100 IL36RN 100 PSMA3 100 TBK1 100 
C1QC 100 DNASE1 100 IL7R 100 PSMB4 100 TBX1 100 
C1R 100 DNASE1L3 100 IRAK4 100 PSMB8 100 TCF3 100 
C1S 100 DNASE2 100 IRF8 100 PSMB9 100 TCN2 100 
C2 99,06 DNMT3B 100 ISG15 100 PSTPIP1 99,53 TERC 100 
C3 100 DOCK2 100 ITCH 100 PTPRC 97,54 TERT 100 
C4A 21,47 DOCK8 100 ITGB2 100 RAB27A 100 THBD 100 
C4B 27,75 ELANE 100 ITK 100 RAC2 100 TINF2 100 
C5 100 ERCC4 100 JAGN1 100 RAD51 100 TLR3 100 
C6 100 EVER1 100 JAK1 100 RAD51C 100 TMEM173 100 
C7 100 EVER2 100 JAK3 100 RAG1 100 TNFAIP3 100 
C8A 100 EXTL3 100 KIND3 100 RAG2 100 TNFRSF11A 100 
C8B 100 FAAP100 100 KRAS 100 RASGRP1 100 TNFRSF13B 100 
C8G 100 FAAP20 100 LACC1 100 RBCK1 100 TNFRSF13C 100 
C9 96,03 FAAP24 100 LAMTOR2 100 RFX5 100 TNFRSF1A 98,34 
CARD11 100 FADD 100 LCK 100 RFXANK 93,94 TPP2 100 
CARD14 100 FAN1 100 LIG4 100 RFXAP 100 TRAF3 100 
CARD9 100 FANCA 97,66 LPIN2 100 RHOH 100 TREX1 100 
CASP10 100 FANCB 100 LRBA 99,94 RMRP 100 TRIF 100 
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CASP8 100 FANCC 100 LYST 99,99 RNASEH2A 100 TTC7A 100 
CD19 100 FANCD2 99,42 MAGT1 99,4 RNASEH2B 100 TWEAK 100 
CD20 99,57 FANCE 100 MALT1 100 RNASEH2C 100 TYK2 100 
CD21 100 FANCF 100 MAP3K14 100 RNF168 100 UAF1 100 
CD27 100 FANCG 100 MASP1 100 RPL11 100 UBE2T 100 
CD3D 100 FANCI 100 MASP2 100 RPL26 100 UNC119 100 
CD3E 100 FANCL 100 MCM4 100 RPL35A 100 UNC13D 100 
CD3G 99,65 FANCM 100 MDA5 100 RPL5 100 UNC93B1 95,43 
CD3Z 100 FAS 100 MEFV 100 RPS10 100 UNG 100 
CD40 100 FASLG 100 MPL 100 RPS17 15,97 USB1 100 
CD40LG 100 FCN3 100 MRE11 100 RPS19 100 USP1 100 
CD46 100 FOXN1 100 MTHFD1 100 RPS24 100 VPS13B 100 
CD59 100 FOXP3 100 MVK 100 RPS26 100 VPS45 100 
CD70 99,52 FPR1 100 MYD88 100 RPS7 100 WAS 100 
CD79A 100 FUCT1 100 NBN 100 RPSA 100 WDR1 100 
CD79B 100 G6PC 100 NCF1 42,96 RTEL1 100 WIPF1 100 
CD81 100 G6PC3 100 NCF2 100 RUNX1 99,94 WRAP53 100 
CD8A 100 GATA2 100 NCF4 100 SAMHD1 100 XIAP 100 
CEBPE 100 GFI1 100 NFKB2 100 SBDS 92,88 ZAP70 100 





Appendix 3: list of genes included in panel 3 with proportion of target covered in the design (cover.) 
Target ID  Coverage Target ID  Coverage 
AP3B1 94,51 NOP10 100 
C16orf57 100 NRAS 100 
CARD11 99,89 PIK3CD 98,44 
CASP10 99,27 PIK3R1  99,66 
CASP8  99,37 PRKCD 99,71 
CD19 100 RAB27A 100 
CD20 88,4 RAC2 100 
CD40 100 RPL11 100 
CD40LG 99,31 RPL26 100 
CSF3R 100 RPL35A 100 
CTC1  93,27 RPL5 100 
CTLA4 100 RPS10 100 
CXCR4 100 RPS17 99,13 
DKC1  99,47 RPS19 100 
ELA2 90,61 RPS24 97,85 
FADD 92,77 RPS26 100 
FAS 99,38 RPS7 100 
FASLG 100 RTEL1 97,94 
G6PC 98,99 SBDS 100 
GFI1 97,52 SLC37A4 99,36 
HAX1 99,97 TAZ 83,98 
ITK 98,35 TERT 88,74 
JAGN1 100 TINF2 100 
KRAS 100 TNFRSF13B 89,38 
LAMTOR2  88,75 TNFRSF13C 33,85 
LRBA 99,94 VPS13B 96,48 
LYST 99,97 VPS45 96,7 
MAGT1 100 WAS 86 
NHP2 100 WRAP53 98,8 
 
